AX-2026-043072 · Exenatide · KP lot KP-2511-W5891

Section 1

Results

Measured against the index acceptance specification for the incretin analogues and co-agonists class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	98.18	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.82	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — Trp25 oxidation (+16 Da)	0.79	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	4183.9370	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, unit resolution (single quadrupole)	4183.9550	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+4.3	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	90.60	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	88.95	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	5.29	mg	5 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	4.705	mg	5 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	94.1	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.00	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.61	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.79	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	1.68	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.98	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	8.07	min	8.06 ± 0.40 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.92	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	72,198	—	≥ 20,000	PASS
Resolution to nearest impurity	vs C-terminal free acid (+1 Da)	1.38	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 72,198, and skew follows the reported asymmetry factor of 0.92. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.79 % impurity against a 98.18 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Exenatide — main peak	8.07	4,771,852	98.18	—
2	Trp25 oxidation (+16 Da)	7.71	38,396	0.79	+15.995
3	Met14 sulfoxide (+16 Da)	7.63	27,218	0.56	+15.995
4	des-Gly1 truncate (−57 Da)	7.86	13,609	0.28	-57.021
5	C-terminal free acid (+1 Da)	8.24	5,346	0.11	+0.984
6	truncated (1-38)	7.79	3,888	0.08	-156.101
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 4183.9370 Da, computed from C184H282N50O60S. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, unit-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 4183.9550 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
6+	698.3301	698.3331	0.0030	8.1
5+	837.7947	837.7983	0.0036	56.0
4+	1046.9915	1046.9960	0.0045	100.0
3+	1395.6529	1395.6589	0.0060	61.0
2+	2092.9758	2092.9848	0.0090	9.3

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.00
Counter-ion (acetate)	ion chromatography	5.61
Residual solvent + inorganic residue	estimated	0.79
Total peptide content	by difference	90.60
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.0	98.18	divergence +0.82 pp vs batch median
Total impurities (% area)	1.00	1.82
Largest single impurity (% area)	0.43	0.79
Water (%)	3.2	3.00
Counter-ion (%)	not stated	5.61
Peptide content (%w/w)	not stated	90.60
Endotoxin (EU/mg)	not stated	1.68
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 25 d) → laboratory (courier, dry ice, 3 d) → assay.
Assay date: 24 Feb 2026
Submitted to the index: 14 Mar 2026
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: METHOD LIMITED

What this report does not establish

That the compound is not a near-isobaric alternative. Identity was confirmed at unit mass resolution, which cannot exclude species differing by 1 or 2 Da. The specific alternatives not excluded are named in the identity block above.
That mass-identical impurities are absent. The gradient used is shorter than the index reference method and does not resolve the diastereomers named in the compound fingerprint. The purity figure is an upper bound.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot KP-2511-W5891 n=7

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-043068	KP-2511-W5891	Janoshik	2026-Q1	98.58	3.70	—	Buyer-sourced	PASS
AX-2026-043069	KP-2511-W5891	Janoshik	2026-Q1	98.16	3.85	95.4	Buyer-sourced	PASS
AX-2026-043070	KP-2511-W5891	Medutest	2026-Q1	98.34	3.73	104.3	Buyer-sourced	PASS
AX-2026-043071	KP-2511-W5891	PeptideMeter	2026-Q1	97.87	3.61	—	Buyer-sourced	FAIL
AX-2026-043073	KP-2511-W5891	Nordanalyt	2026-Q1	98.97	3.52	—	Supplier-supplied	PASS
AX-2026-043074	KP-2511-W5891	Janoshik	2026-Q1	97.91	4.08	91.0	Buyer-sourced	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Exenatide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041808	ASY	ASY-{CAT}-2827	Janoshik	2026-Q2	99.32	4.59	95.7	Buyer-sourced	0	PASS
AX-2026-041803	ASY	ASY-{CAT}-2827	Medutest	2026-Q2	99.61	4.99	—	Buyer-sourced	0	PASS
AX-2026-041804	ASY	ASY-{CAT}-2827	VendorInvestigate	2026-Q2	99.12	4.76	98.0	Buyer-sourced	0	PASS
AX-2026-041802	ASY	ASY-{CAT}-2827	Janoshik	2026-Q2	99.44	4.12	106.6	Buyer-sourced	0	PASS
AX-2026-041810	ASY	ASY-{CAT}-2827	VendorInvestigate	2026-Q2	99.23	4.33	—	Laboratory-retained	0	PASS
AX-2026-041809	ASY	ASY-{CAT}-2827	Nordanalyt	2026-Q2	99.70	4.39	98.7	Buyer-sourced	1	MARGINAL
AX-2026-041811	ASY	ASY-{CAT}-2827	Janoshik	2026-Q2	99.29	4.64	—	Buyer-sourced	0	PASS
AX-2026-041801	ASY	ASY-{CAT}-2827	Nordanalyt	2026-Q2	99.34	4.76	—	Buyer-sourced	1	MARGINAL

Other recent KP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043095	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	95.81	5.48	105.2	Buyer-sourced	0	FAIL
AX-2026-043094	Retatrutide	KP-2607-H5774	PeptideMeter	2026-Q3	96.32	6.40	—	Buyer-sourced	0	FAIL
AX-2026-043096	Retatrutide	KP-2607-H5774	VendorInvestigate	2026-Q3	96.48	6.05	104.9	Buyer-sourced	0	FAIL
AX-2026-043090	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	96.46	5.81	—	Buyer-sourced	0	FAIL
AX-2026-043091	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	96.13	5.94	—	Buyer-sourced	0	FAIL
AX-2026-043077	TB-500	KP-2605-C5214	Janoshik	2026-Q2	99.61	5.64	90.2	Buyer-sourced	0	PASS
AX-2026-043093	Retatrutide	KP-2607-H5774	Janoshik	2026-Q3	96.54	5.54	—	Buyer-sourced	0	PASS
AX-2026-043092	Retatrutide	KP-2607-H5774	Medutest	2026-Q3	96.64	6.12	—	Buyer-sourced	1	FAIL